ArticleNature communications2017
A point-of-care microfluidic biochip for quantification of CD64 expression from whole blood for sepsis stratification.
Article in Nature communications, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 140 citations in OpenAlex.
- Valuable Role of Neutrophil CD64 and Highly Sensitive CRP Biomarkers for Diagnostic, Monitoring, and Prognostic Evaluations of Sepsis Patients in Neonatal ICUs.BioMed research international · 2020Trial
- Recent advances in the biosensing platforms for sepsis diagnosis.RSC advances · 2026Review
- Leveraging laboratory biomarkers to predict urosepsis after upper urinary tract stone surgery: an explainable machine learning approach.BMC medical informatics and decision making · 2025Article
- Advances toward At-Home Measurements of Complete Blood Cell Counts and Other Hematological Parameters.Analytical chemistry · 2025Review
- Point of care sepsis diagnosis: Exploring microfluidic techniques for sample preparation, biomarker isolation, and detection.Biomicrofluidics · 2025Review
- Plasmonic coffee-ring biosensing for AI-assisted point-of-care diagnostics.Nature communications · 2025Article
- Neutrophil CD64 can be an early predictor for sepsis during febrile neutropenic episodes in children with cancer: a case control study.Italian journal of pediatrics · 2025Article
- The Role of Neutrophil CD11b Compared to Neutrophil CD64 as an Early Diagnostic, Monitoring, and Prognostic Sepsis Marker in Neonatal ICUs: Case-Control-Methodological Study.BioMed research international · 2025Article
- Micropump integrated white blood cell separation platform for detection of chronic granulomatous disease.Mikrochimica acta · 2024Article
- Multiplexed electrical detection of whole viruses from plasma in a microfluidic platform.The Analyst · 2024Article
- Enabling biomedical technologies for chronic myelogenous leukemia (CML) biomarkers detection.Biomicrofluidics · 2024Review
- Multi-modal sensing with integrated machine learning to differentiate specific leukocytes targeted by electrically sensitive hybrid particles.Biosensors & bioelectronics · 2023Article
- Electrochemical point-of-care devices for the diagnosis of sepsis.Current opinion in electrochemistry · 2023Article
- Porous Structural Microfluidic Device for Biomedical Diagnosis: A Review.Micromachines · 2023Review
- Antibody-functionalized aluminum oxide-coated particles targeting neutrophil receptors in a multifrequency microfluidic impedance cytometer.Lab on a chip · 2022Article
- Developments of Conventional and Microfluidic Flow Cytometry Enabling High-Throughput Characterization of Single Cells.Biosensors · 2022Review
- Emerging biosensing and transducing techniques for potential applications in point-of-care diagnostics.Chemical science · 2022Review
- Micro- and nanosensors for detecting blood pathogens and biomarkers at different points of sepsis care.Mikrochimica acta · 2022Review
- Immunomonitoring of Monocyte and Neutrophil Function in Critically Ill Patients: From Sepsis and/or Trauma to COVID-19.Journal of clinical medicine · 2021Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sepsis, a potentially life-threatening complication of an infection, has the highest burden of death and medical expenses in hospitals worldwide. Leukocyte count and CD64 expression on neutrophils (nCD64) are known to correlate strongly with improved sensitivity and specificity of sepsis diagnosis at its onset. A major challenge is the lack of a rapid and accurate point-of-care (PoC) device that can perform these measurements from a minute blood sample. Here, we report a PoC microfluidic biochip to enumerate leukocytes and quantify nCD64 levels from 10 μl of whole blood without any manual processing. Biochip measurements have shown excellent correlation with the results from flow cytometer. In clinical studies, we have used PoC biochip to monitor leukocyte counts and nCD64 levels from patients' blood at different times of their stay in the hospital. Furthermore, we have shown the biochip's utility for improved sepsis diagnosis by combining these measurements with electronic medical record (EMR).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.